Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICI Pharma's Nolvadex (tamoxifen)

Executive Summary

ICI Pharma's Nolvadex (tamoxifen): Anti-estrogen drug receives supplemental approval for use in treating breast cancer in premenopausal women, as alternative to mastectomy. The oral hormone product is already indicated as a treatment for postmenopausal breast cancer and for use either alone or in combination with other anticancer agents following surgery in postmenopausal node-positive patients. The company estimates the U.S. patient population for the new indication at 14,000: 5,000 women who have advanced disease at diagnosis and 9,000 women with recurring disease.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel